Oculis to Participate in Upcoming September Investor Conferences

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [5] - The management team will participate in several investor conferences in September 2025, including the Wells Fargo Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference [2][3] Company Overview - Oculis has a differentiated late-stage clinical pipeline with three core product candidates: OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease [5] - The company is headquartered in Switzerland and has operations in the U.S. and Iceland, led by an experienced management team supported by international healthcare investors [5] Upcoming Events - Key events include: - Wells Fargo Healthcare Conference from September 3-5 in Boston, U.S. [2] - H.C. Wainwright 27th Annual Global Investment Conference from September 8-10 in New York, U.S. [3] - Baird Global Healthcare Conference on September 9-10 in New York, U.S. [3] - Pareto Securities 16th Annual Healthcare Conference on September 16 in Stockholm, Sweden [3] - Leerink Partners Biopharma Summit from September 17-19 in Healdsburg, U.S. [4] - The company will be available for one-on-one meetings during these conferences [4]